Report Summary

The global gout therapeutics market size is expected to be valued at USD 2,442.8 million in 2019 and is anticipated to grow at a CAGR of 14.8% during the forecast period. Gout is a severe form of arthritis that can result in sudden attacks of pains in the joints. It is characterized by severe pain, tenderness and redness in joints. It most commonly develops in the ball of the big toe. Joints in the ankles, feet, heels, wrists, knees, elbows, and hands can also be affected. There are several therapeutic alternatives available in the market for gout. NSAID’s or corticosteroids can be used for pain and inflammation caused in this condition. Furthermore, people suffering with multiple acute gout attacks per year or people who have tophi on exam are mainly suggested the uric acid lowering therapy. In order to prevent this condition, all the patients are encouraged to modify their lifestyle and bring some changes in their daily habits, including, encouraging weight loss where appropriate, limiting alcohol intake and decreasing food rich in purines.

The gout therapeutics market is primarily driven by increasing prevalence of this condition, due to changing lifestyle pattern and growing geriatric population. Globally, the life expectancy of people is increasing which has led to rise in the geriatric population. This trend has led to a higher incidence of this condition and per capita demand for its therapeutics, thus positively affecting the demand for these therapeutics. Furthermore, growing research and development activities focusing on innovation and development of gout therapeutic agents and growing awareness associated with the treatment of gout are further stimulating the industry growth. Additionally, growing innovations in the field of biologics and increasing adoption of these products based on their ability to produce powerful anti-inflammatory action is also expected to drive the growth of this market during the forecast period. Moreover, there are large number of clinical trials in process, due to which many new products are expected to be launched in coming few years. This is also expected to propel the industry growth during the forecast period. However, factors such as increasing competition in the generic sector, patent expiry of blockbuster products, and high cost of the newly launched drugs are likely to hinder the growth of this industry during the forecast period.

Know more about this report: request for sample pages

Until recently, diagnosis and treatment of gout in patients with associated metabolic syndrome and comorbid illnesses was difficult mainly because of limited treatment options. However, with time, significant progress has been made in this field and new treatments such as interleukin-1 antagonists, febuxostat and pegloticase were introduced. Currently, biological therapies are a major focus of the researchers, which target specific elements of the immune system that play a key role in pathogenesis. Several new biologics such as Canakinumab, Krystexxa, and Rilonacept have been introduced in the market. As, there is rapid development in the process of understanding and managing the condition of gout, several therapies are being introduced and thus, are creating growth opportunities in this marketplace.

Various products such as non-steroidal anti-inflammatory drugs (nsaids), corticosteroids, colchicine, and urate lowering agents are used as treatment option for the patients suffering with gout. Companies operating in this industrial segment are continuously investing in research and development to improve the product efficacies are offer more appropriate and effective products. Numerous studies are being funded by government and private organizations across the globe. In October 2018, University of Otago was funded by the Royal Society Te Aparangi for research into the genetic causes of gout and related diseases in New Zealand. Furthermore, companies such as AstraZeneca, Horizon Pharma, Takeda Pharmaceutical, GlaxoSmithKline, Novartis, Merck & Co., and many others are launching and distributing new products in the market. For instance, in February 2016 AstraZeneca received marketing authorisation for Zurampic (lesinurad) from the European Commission (EC). Furthermore, in September 2019, Simcere Pharmaceutical Group entered into a collaboration and exclusive license agreement with JW Pharmaceutical, for anti-gout drug candidate URC-102 in China. Such activities are helping the companies enhance their presence and thus, drive the growth across the globe.

Gout Therapeutics Market Report Scope

The market is primarily segmented on the basis of drug class, disease condition, and geographic region.

By Drug Class By Disease Condition By Region Non-steroidal Anti-Inflammatory Drugs (NSAIDs)

Corticosteroids

Colchicine

Urate Lowering Agents Acute

Chronic North America (U.S., Canada)

Europe (Germany, UK, France, Italy, Spain, Belgium, Rest of Europe)

Asia-Pacific (China, India, Japan, South Korea, Australia, Rest of Asia-Pacific)

Latin America (Brazil, Mexico, Rest of LATAM)

Middle East and Africa (South Africa, Saudi Arabia, Rest of MEA)

Know more about this report: request for sample pages

Drug Class Outlook

Based on drug class, the global gout therapeutics industry is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, colchicine, and urate lowering agents. In 2019, NSAIDs accounted for the largest share in the industry. NSAIDs are the first line drugs used to decrease the inflammation and the associated pain of rheumatic and non-rheumatic diseases. Rising number of gout patients, low cost of drugs, and application in combination therapy is likely to drive the market Indomethacin and naproxen are major choice for the acute attack of the gout. Urate lowering agents segment is expected to observe the highest growth during the forecast period. This is attributed to recently introduction of novel drugs, investment by several industry players for the development of urate lowering agents, and expected launch of anti-gout drugs during the forecast period. The growth of colchicine segment is also significant based on its efficacy and growing product development activities.

In February 2019, ROMEG therapeutics received FDA approval of GLOPERBA (colchicine) for prophylaxis of adult gout flares.

Disease Condition Outlook

On the basis of disease condition, the industry is segmented into acute and chronic gout. In 2019, chronic segment accounted for the highest share of the market. This is attributed to introduction or commercialization of various drugs for chronic conditions and high cost of medicine. Urate lowering agents are utilized in chronic conditions. Whereas, colchicine, NSAIDs, and corticosteroids are preferred in acute.

The acute segment consists of colchicine, NSAIDs, and corticosteroids therapy. The segment accounted lesser share as compared to chronic therapeutics. This is attributed to low cost drugs, low adherence to the treatment, and drugs ability to relieve pain for shorter period. More penetration of therapeutics for acute conditions due to their early entry into market and low cost were the major driving factor for acute gout therapeutics segment.

Regional Outlook

North America dominated the industry due to due to the presence of major market players, affordability for high cost biologics and urate lowering agents, early introduction of drugs in the US, and presence of large patient base. Gout is common in most countries in North America affecting around 8.3 million people in the United States, with prevalence in the 1–4% range. The prevalence of gout is higher in African Americans as compared to Caucasians, with increasing prevalence overall across all demographics. The U.S. accounted for highest share in the North American region for this industry. Government initiatives to provide better healthcare facilities to all their residents, favorable reimbursement, presence of major market players, and high adoption of the high cost therapeutics are the key factors for the dominance of the market.

However, Asia Pacific is expected to observe the fastest growth during the forecast period due to increasing investment of market players in the region, rising awareness and healthcare spending, and expected entry of drugs in the region. Furthermore, rising patient pool, increasing investment by major players in the region, and rising adoption of gout therapy are also fueling the growth of this regional segment. Moreover, increasing prevalence of smoking & alcohol consumption and stressed lifestyle are likely to boost the incidence of gout during the forecast period.

Competitive Landscape

Companies are expanding their presence across various geographies and entering new markets in developing regions to expand their customer base and strengthen presence in the market. The companies are also introducing new innovative products in the market to cater to the growing consumer demands. The key leading players in the market include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.